Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01009242 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate
A Phase 1 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01009242 is a Phase 1 study that has completed, run by UCB Pharma. The registered enrollment target is 40 participants.
The verdict
NCT01009242, a Phase 1 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objectives are to determine the relationship between blood levels of CDP6038 and suppression of C-reactive Protein (CRP) following single doses given as intravenous (IV) infusion or subcutaneous (SC) injection to Rheumatoid Arthritis (RA) patients. The safety of CDP6038 will also be evaluated.
Interventions
- OTHER Placebo IV
- BIOLOGICAL CDP6038
- OTHER Placebo SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01009242
The ClinicalTrials.gov registry entry for NCT01009242 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo IV is the first listed.
NCT01009242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01009242 about?
NCT01009242 is a clinical study titled "To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate". The primary objectives are to determine the relationship between blood levels of CDP6038 and suppression of C-reactive Protein (CRP) following single doses given as intravenous (IV) infusion or subcutaneous (SC) injection to Rheumatoid Arthritis (RA) patients. The safety of CDP6038 will also be eval...
What is the current status of trial NCT01009242?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2009-10. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01009242?
The interventions under investigation include: Placebo IV (OTHER), CDP6038 (BIOLOGICAL), Placebo SC (OTHER).
Who is sponsoring clinical trial NCT01009242?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.